Skip to main content
Lisa Carey, MD, Oncology, Chapel Hill, NC

LisaACareyMD

Oncology Chapel Hill, NC

Professor of Hematology & Oncology, University of North Carolina School of Medicine

Dr. Carey is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Carey's full profile

Already have an account?

  • Office

    101 Manning Dr
    Chapel Hill, NC 27514
    Phone+1 919-966-4996
    Fax+1 919-843-5515

Education & Training

  • Johns Hopkins University
    Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1993 - 1997
  • Johns Hopkins University
    Johns Hopkins UniversityResidency, Internal Medicine, 1990 - 1993
  • Johns Hopkins University School of Medicine
    Johns Hopkins University School of MedicineClass of 1990

Certifications & Licensure

  • NC State Medical License
    NC State Medical License 1997 - 2025
  • MD State Medical License
    MD State Medical License 1993 - 1998
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2009-2014
  • America's Top Doctors for Cancer Castle Connolly, 2005-2013

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Integrated Analysis of RNA and DNA from a Phase III Trial of Trastuzumab-Based Neoadjuvant Chemotherapy Identifies Response Predictors in HER2-Positive Breast Cancer  
    Lisa Carey, MD, Clinical Cancer Research

Lectures

  • HER2-Targeted Therapy: Changing the Story of Breast Cancer 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018

Authored Content

  • Key Immunotherapy Presentations in Early Breast Cancer from ESMO 2023: KEYNOTE-756, CheckMate-7FL, and Updated KEYNOTE-522October 2023
  • Endocrine-Based Therapy for Early and Metastatic Breast Cancer: New Horizons from ASCO 2023June 2023

Press Mentions

  • Association of Immune-Related Gene Expression Signatures and TILs with Outcomes in Early-Stage HER2-Positive Breast Cancer
    Association of Immune-Related Gene Expression Signatures and TILs with Outcomes in Early-Stage HER2-Positive Breast CancerJanuary 31st, 2023
  • Immune-Related Biomarkers Can Help Guide HER2+ Breast Cancer Tx
    Immune-Related Biomarkers Can Help Guide HER2+ Breast Cancer TxJanuary 24th, 2023
  • Study Identifies Molecular Differences Between Primary Breast Cancer and Its Metastases
    Study Identifies Molecular Differences Between Primary Breast Cancer and Its MetastasesJanuary 9th, 2023
  • Join now to see all

Grant Support

  • Breast Cancer ResearchNational Cancer Institute2011–2012
  • Academic Training In Oncology At The University Of North Carolina At Chapel HillNational Cancer Institute2011
  • Developmental Research ProgramNational Cancer Institute2006–2010
  • Lccc 0403: Phase II Cetuximab Alone And In Combination With CarboplatinNational Center For Research Resources2007
  • Lccc 9818: Stage IIB, Stage IIIA/B Stage IV Breast CancerNational Center For Research Resources2004–2006
  • Correlation Of Marker With Response To ChemotherapyNational Cancer Institute2001–2002
  • Tamoxifen &Raloxifene For Preventtion Of Breast CancerNational Center For Research Resources2000
  • Molecular Markers W/ Response To Chemotherapy In Breast CANational Center For Research Resources2000
  • Doxorubicin &Cyclophosphamide &Paclitaxel W/ HerceptinNational Center For Research Resources2000

Professional Memberships